Phenotypic lead generation strategies seek to identify compounds that modulate complex, physiologically relevant systems, an approach that is complementary to traditional, target-directed strategies. Unlike gene-specific assays, phenotypic assays interrogate multiple molecular targets and signaling pathways in a target “agnostic” fashion, which may reveal novel functions for well-studied proteins and discover new pathways of therapeutic value. Significantly, existing compound libraries may not have sufficient chemical diversity to fully leverage a phenotypic strategy. To address this issue, Eli Lilly and Company launched the Phenotypic Drug Discovery Initiative (PD2), a model of open innovation whereby external research groups can submit compounds for testing in a panel of Lilly phenotypic assays. This communication describes the statistical validation, operations, and initial screening results from the first PD2 assay panel. Analysis of PD2 submissions indicates that chemical diversity from open source collaborations complements internal sources. Screening results for the first 4691 compounds submitted to PD2 have confirmed hit rates from 1.6% to 10%, with the majority of active compounds exhibiting acceptable potency and selectivity. Phenotypic lead generation strategies, in conjunction with novel chemical diversity obtained via open-source initiatives such as PD2, may provide a means to identify compounds that modulate biology by novel mechanisms and expand the innovation potential of drug discovery.
Lee J. A.,Cox K.,Kriauciunas A.,Chu S.High Content Screening: Science, Techniques, and Applications. Haney S, ed. New York: John Wiley and Sons; 2008:249-268.
2.
Low J.,Stancato L.,Lee J.,Sutherland J. J..Prioritizing Hits from Phenotypic High-Content Screens.Curr. Opin. Drug. Discov. Dev. 2008;11:338-345
3.
Mayer T. U.,Kapoor T. M.,Haggarty S. J.,King R. W.,Schreiber S. L.,Mitchison T. J..Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen.Science. 1999;286:971-974
4.
Yarrow J. C.,Totsukawa G.,Charras G. T.,Mitchison T. J..Screening for Cell Migration Inhibitors via Automated Microscopy Reveals a Rho-Kinase Inhibitor.Chem. Biol. 2005;12:385-395
5.
Chen S.,Do J. T.,Zhang Q.,Yao S.,Yan F.,Peters E. C.,Scholer H. R.,Schultz P. G.,Ding S..Self-Renewal of Embryonic Stem Cells by a Small Molecule.Proc. Natl. Acad. Sci. U. S. A. 2006;103:17266-17271
6.
Davis S.,Granner D.Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001:1679-1714.
7.
Cadigan K. M.,Nusse R..Wnt Signaling: A Common Theme in Animal Development.Genes Dev. 1997;11:3286-3305
8.
Krishnan V.,Bryant H. U.,Macdougald O. A..Regulation of Bone Mass by Wnt Signaling.J. Clin. Invest. 2006;116:1202-1209
9.
Strittmatter W. J.,Saunders A. M.,Schmechel D.,Pericak-Vance M.,Enghild J.,Salvesen G. S.,Roses A. D..Apolipoprotein E: High-Avidity Binding to Beta-Amyloid and Increased Frequency of Type 4 Allele in Late-Onset Familial Alzheimer Disease.Proc. Natl. Acad. Sci. U. S. A. 1993;90:1977-1981
10.
Corder E. H.,Saunders A. M.,Strittmatter W. J.,Schmechel D. E.,Gaskell P. C.,Small G. W.,Roses A. D.,Haines J. L.,Pericak-Vance M. A..Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer’s Disease in Late Onset Families.Science. 1993;261:921-923
11.
Chabner B. A.,Allegra C. J.,Curt G. A.,Calabresi P.Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996:1233-1287.
12.
Folkman J..Angiogenesis: An Organizing Principle for Drug Discovery?.Nat. Rev. Drug Discov. 2007;6:273-286
13.
Atkins M.,Jones C. A.,Kirkpatrick P..Sunitinib Maleate.Nat. Rev. Drug. Discov. 2006;5:279-280
14.
Adams R. H.,Alitalo K..Molecular Regulation of Angiogenesis and Lymphangiogenesis.Nat. Rev. Mol. Cell Biol. 2007;8:464-478
15.
Willert K.,Brown J. D.,Danenberg E.,Duncan A. W.,Weissman I. L.,Reya T.,Yates J. R.,Nusse R..Wnt Proteins Are Lipid-Modified and Can Act as Stem Cell Growth Factors.Nature. 2003;423:448-452
16.
Iversen P. W.,Eastwood B. J.,Sittampalam G. S.,Cox K. L..A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z′ Factor, and Assay Variability Ratio.J. Biomol. Screen. 2006;11:247-252
17.
Zhang J. H.,Chung T. D.,Oldenburg K. R..A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.J. Biomol. Screen. 1999;4:67-73
18.
Eastwood B. J.,Farmen M. W.,Iversen P. W.,Craft T. J.,Smallwood J. K.,Garbison K. E.,Delapp N. W.,Smith G. F..The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies.J. Biomol. Screen. 2006;11:253-261
19.
Asfari M.,Janjic D.,Meda P.,Li G.,Halban P. A.,Wollheim C. B..Establishment of 2-Mercaptoethanol-Dependent Differentiated Insulin-Secreting Cell Lines.Endocrinology. 1992;130:167-178
20.
Matschinsky F. M..Assessing the Potential of Glucokinase Activators in Diabetes Therapy.Nat. Rev. Drug Discov. 2009;8:399-416
21.
Efanov A. M.,Barrett D. G.,Brenner M. B.,Briggs S. L.,Delaunois A.,Durbin J. D.,Giese U.,Guo H.,Radloff M.,Gil G. S.,Sewing S.,Wang Y.,Weichert A.,Zaliani A.,Gromada J..A Novel Glucokinase Activator Modulates Pancreatic Islet and Hepatocyte Function.Endocrinology. 2005;146:3696-3701
22.
Brenner M. B.,Gromada J.,Efanov A. M.,Bokvist K.,Mest H. J..Restoration of First-Phase Insulin Secretion by the Imidazoline Compound LY374284 in Pancreatic Islets of Diabetic db/db Mice.Ann. N. Y. Acad. Sci. 2003;1009:332-340
23.
Efanov A. M.,Zaitsev S. V.,Mest H. J.,Raap A.,Appelskog I. B.,Larsson O.,Berggren P. O.,Efendic S..The Novel Imidazoline Compound BL11282 Potentiates Glucose-Induced Insulin Secretion in Pancreatic Beta-Cells in the Absence of Modulation of K(ATP) Channel Activity.Diabetes. 2001;50:797-802
24.
Malaisse W. J.,Sener A.,Herchuelz A.,Carpinelli A. R.,Poloczek P.,Winand J.,Castagna M..Insulinotropic Effect of the Tumor Promoter 12-O-Tetradecanoylphorbol-13-Acetate in Rat Pancreatic Islets.Cancer Res. 1980;40:3827-3831
25.
Krul E. S.,Tang J..Secretion of Apolipoprotein E by an Astrocytoma Cell Line.J. Neurosci. Res. 1992;32:227-238
26.
Schultz J. R.,Tu H.,Luk A.,Repa J. J.,Medina J. C.,Li L.,Schwendner S.,Wang S.,Thoolen M.,Mangelsdorf D. J.,Lustig K. D.,Shan B..Role of LXRs in Control of Lipogenesis.Genes Dev. 2000;14:2831-2838
27.
Liang Y.,Lin S.,Beyer T. P.,Zhang Y.,Wu X.,Bales K. R.,DeMattos R. B.,May P. C.,Li S. D.,Jiang X. C.,Eacho P. I.,Cao G.,Paul S. M..A Liver X Receptor and Retinoid X Receptor Heterodimer Mediates Apolipoprotein E Expression, Secretion and Cholesterol Homeostasis in Astrocytes.J. Neurochem. 2004;88:623-634
28.
Stein G. S.,Lian J. B.,Stein J. L.,Van Wijnen A. J.,Montecino M..Transcriptional Control of Osteoblast Growth and Differentiation.Physiol. Rev. 1996;76:593-629
29.
Engler T. A.,Henry J. R.,Malhotra S.,Cunningham B.,Furness K.,Brozinick J.,Burkholder T. P.,Clay M. P.,Clayton J.,Diefenbacher C.,Hawkins E.,Iversen P. W.,Li Y.,Lindstrom T. D.,Marquart A. L.,McLean J.,Mendel D.,Misener E.,Briere D.,O’Toole J. C.,Porter W. J.,Queener S.,Reel J. K.,Owens R. A.,Brier R. A.,Eessalu T. E.,Wagner J. R.,Campbell R. M.,Vaughn R..Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-dion Is a Highly Selective and Potent Inhibitor of Glycogen Synthase Kinase-3.J. Med. Chem. 2004;47:3934-3937
30.
Barabasz A.,Foley B.,Otto J. C.,Scott A.,Rice J..The Use of High-Content Screening for the Discovery and Characterization of Compounds That Modulate Mitotic Index and Cell Cycle Progression by Differing Mechanisms of Action.Assay Drug. Dev. Technol. 2006;4:153-163
Grove L. E.,Ghosh R. N..Quantitative Characterization of Mitosis-Blocked Tetraploid Cells Using High Content Analysis.Assay Drug Dev. Technol. 2006;4:421-442
33.
Kerr J. F.,Wyllie A. H.,Currie A. R..Apoptosis: A Basic Biological Phenomenon with Wide-Ranging Implications in Tissue Kinetics.Br. J. Cancer. 1972;26:239-257
34.
Snyder J. A.,Hamilton B. T.,Mullins J. M..Loss of Mitotic Centrosomal Microtubule Initiation Capacity at the Metaphase-Anaphase Transition.Eur. J. Cell. Biol. 1982;27:191-199
35.
Martin Y. C.,Kofron J. L.,Traphagen L. M..Do Structurally Similar Molecules Have Similar Biological Activity?.J. Med. Chem. 2002;45:4350-4358
36.
Zhou J. R.,Mukherjee P.,Gugger E. T.,Tanaka T.,Blackburn G. L.,Clinton S. K..Inhibition of Murine Bladder Tumorigenesis by Soy Isoflavones via Alterations in the Cell Cycle, Apoptosis, and Angiogenesis.Cancer Res. 1998;58:5231-5238
37.
Ahren B..Islet G Protein-Coupled Receptors as Potential Targets for Treatment of Type 2 Diabetes.Nat. Rev. Drug Discov. 2009;8:369-385
38.
Wu W.,Shang J.,Feng Y.,Thompson C. M.,Horwitz S.,Thompson J. R.,MacIntyre E. D.,Thornberry N. A.,Chapman K.,Zhou Y. P.,Howard A. D.,Li J..Identification of Glucose-Dependant Insulin Secretion Targets in Pancreatic Beta Cells by Combining Defined-Mechanism Compound Library Screening and siRNA Gene Silencing.J. Biomol. Screen. 2008;13:128-134
39.
Roses A. D..Apolipoprotein E Alleles as Risk Factors in Alzheimer’s Disease.Annu. Rev. Med. 1996;47:387-400
40.
Holtzman D. M.,Fagan A. M.,Mackey B.,Tenkova T.,Sartorius L.,Paul S. M.,Bales K.,Ashe K. H.,Irizarry M. C.,Hyman B. T..Apolipoprotein E Facilitates Neuritic and Cerebrovascular Plaque Formation in an Alzheimer’s Disease Model.Ann. Neurol. 2000;47:739-747
41.
Ji Y.,Gong Y.,Gan W.,Beach T.,Holtzman D. M.,Wisniewski T..Apolipoprotein E Isoform-Specific Regulation of Dendritic Spine Morphology in Apolipoprotein E Transgenic Mice and Alzheimer’s Disease Patients.Neuroscience. 2003;122:305-315
42.
Jiang Q.,Lee C. Y.,Mandrekar S.,Wilkinson B.,Cramer P.,Zelcer N.,Mann K.,Lamb B.,Willson T. M.,Collins J. L.,Richardson J. C.,Smith J. D.,Comery T. A.,Riddell D.,Holtzman D. M.,Tontonoz P.,Landreth G. E..ApoE Promotes the Proteolytic Degradation of Abeta.Neuron. 2008;58:681-693
43.
Deane R.,Sagare A.,Hamm K.,Parisi M.,Lane S.,Finn M. B.,Holtzman D. M.,Zlokovic B. V..apoE Isoform-Specific Disruption of Amyloid Beta Peptide Clearance from Mouse Brain.J. Clin. Invest. 2008;118:4002-4013
44.
Riddell D. R.,Zhou H.,Comery T. A.,Kouranova E.,Lo C. F.,Warwick H. K.,Ring R. H.,Kirksey Y.,Aschmies S.,Xu J.,Kubek K.,Hirst W. D.,Gonzales C.,Chen Y.,Murphy E.,Leonard S.,Vasylyev D.,Oganesian A.,Martone R. L.,Pangalos M. N.,Reinhart P. H.,Jacobsen J. S..The LXR Agonist TO901317 Selectively Lowers Hippocampal Abeta42 and Improves Memory in the Tg2576 Mouse Model of Alzheimer’s Disease.Mol. Cell Neurosci. 2007;34:621-628
45.
Grefhorst A.,Elzinga B. M.,Voshol P. J.,Plosch T.,Kok T.,Bloks V. W.,van der Sluijs F. H.,Havekes L. M.,Romijn J. A.,Verkade H. J.,Kuipers F..Stimulation of Lipogenesis by Pharmacological Activation of the Liver X Receptor Leads to Production of Large, Triglyceride-Rich Very Low Density Lipoprotein Particles.J. Biol. Chem. 2002;277:34182-34190
46.
Starck M.,Bertrand P.,Pepin S.,Schiele F.,Siest G.,Galteau M. M..Effects of Pro-Inflammatory Cytokines on Apolipoprotein E Secretion by a Human Astrocytoma Cell Line (CCF-STTG1).Cell Biochem. Funct. 2000;18:9-16
47.
Case N.,Rubin J..β-catenin—A Supporting Role in the Skeleton.J. Cell Biochem. 2010;110:545-553
48.
Hoeppner L. H.,Secreto F. J.,Westendorf J. J..Wnt Signaling as a Therapeutic Target for Bone Diseases.Expert Opin. Ther. Targets. 2009;13:485-496
49.
Zhang Q.,Major M. B.,Takanashi S.,Camp N. D.,Nishiya N.,Peters E. C.,Ginsberg M. H.,Jian X.,Randazzo P. A.,Schultz P. G.,Moon R. T.,Ding S..Small-Molecule Synergist of the Wnt/ Beta-Catenin Signaling Pathway.Proc. Natl. Acad. Sci. U. S. A. 2007;104:7444-7448
50.
Borchert K. M.,Galvin R. J.,Frolik C. A.,Hale L. V.,Halladay D. L.,Gonyier R. J.,Trask O. J.,Nickischer D. R.,Houck K. A..High-Content Screening Assay for Activators of the Wnt/Fzd Pathway in Primary Human Cells.Assay Drug Dev. Technol. 2005;3:133-141
51.
Borchert K. M.,Sells Galvin J.,Hale L. V.,Trask O. J.,Nickischer D. R.,Houck K. A..Screening for Activators of the Wingless Type/Frizzled Pathway by Automated Fluorescent Microscopy.Methods Enzymol. 2006;414:140-150
52.
Katagiri T.,Yamaguchi A.,Komaki M.,Abe E.,Takahashi N.,Ikeda T.,Rosen V.,Wozney J. M.,Fujisawa-Sehara A.,Suda T..Bone Morphogenetic Protein-2 Converts the Differentiation Pathway of C2C12 Myoblasts into the Osteoblast Lineage.J. Cell. Biol. 1994;127:1755-1766
53.
Lee K. S.,Kim H. J.,Li Q. L.,Chi X. Z.,Ueta C.,Komori T.,Wozney J. M.,Kim E. G.,Choi J. Y.,Ryoo H. M.,Bae S. C..Runx2 Is a Common Target of Transforming Growth Factor Beta1 and Bone Morphogenetic Protein 2, and Cooperation between Runx2 and Smad5 Induces Osteoblast-Specific Gene Expression in the Pluripotent Mesenchymal Precursor Cell Line C2C12.Mol. Cell Biol. 2000;20:8783-8792
54.
Tian E.,Zhan F.,Walker R.,Rasmussen E.,Ma Y.,Barlogie B.,Shaughnessy J. D..The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma.N. Engl. J. Med. 2003;349:2483-2494
55.
Yang F.,Tang W.,So S.,Crombrugghe B.,Zhang C..Sclerostin is a direct target of osteoblast-specific transcription factor osterix.Biochem. Biophys. Res. Commun. 2010;400:684-688
56.
Stewart J. P.,Shaughnessy J. D..Role of Osteoblast Suppression in Multiple Myeloma.J. Cell Biochem. 2006;98:1-13
57.
Arnaoutova I.,George J.,Kleinman H. K.,Benton G..The Endothelial Cell Tube Formation Assay on Basement Membrane Turns 20: State of the Science and the Art.Angiogenesis. 2009;12:267-274
58.
Vukicevic S.,Kleinman H. K.,Luyten F. P.,Roberts A. B.,Roche N. S.,Reddi A. H..Identification of Multiple Active Growth Factors in Basement Membrane Matrigel Suggests Caution in Interpretation of Cellular Activity Related to Extracellular Matrix Components.Exp. Cell Res. 1992;202:1-8
59.
Donovan D.,Brown N. J.,Bishop E. T.,Lewis C. E..Comparison of Three In Vitro Human “Angiogenesis” Assays With Capillaries Formed In Vivo.Angiogenesis. 2001;4:113-121
60.
Evensen L.,Micklem D. R.,Blois A.,Berge S. V.,Aarsaether N.,Littlewood-Evans A.,Wood J.,Lorens J. B..Mural Cell Associated VEGF Is Required for Organotypic Vessel Formation.PLoS. One. 2009;4:e5798
61.
Traktuev D. O.,Prater D. N.,Merfeld-Clauss S.,Sanjeevaiah A. R.,Saadatzadeh M. R.,Murphy M.,Johnstone B. H.,Ingram D. A.,March K. L..Robust Functional Vascular Network Formation In Vivo by Cooperation of Adipose Progenitor and Endothelial Cells.Circ. Res. 2009;104:1410-1420
62.
Yoder M. C..Is Endothelium the Origin of Endothelial Progenitor Cells?.Arterioscler. Thromb. Vasc. Biology. 2010;30:1094-1103
63.
Amos P. J.,Shang H.,Bailey A. M.,Taylor A.,Katz A. J.,Peirce S. M..IFATS Collection: The Role of Human Adipose-Derived Stromal Cells in Inflammatory Microvascular Remodeling and Evidence of a Perivascular Phenotype.Stem Cells. 2008;26:2682-2690
64.
Traktuev D. O.,Merfeld-Clauss S.,Li J.,Kolonin M.,Arap W.,Pasqualini R.,Johnstone B. H.,March K. L..A Population of Multipotent CD34-Positive Adipose Stromal Cells Share Pericyte and Mesenchymal Surface Markers, Reside in a Periendothelial Location, and Stabilize Endothelial Networks.Circ. Res. 2008;102:77-85
65.
Gimble J. M.,Katz A. J.,Bunnell B. A..Adipose-Derived Stem Cells for Regenerative Medicine.Circ. Res. 2007;100:1249-1260
66.
Crisan M.,Yap S.,Casteilla L.,Chen C. W.,Corselli M.,Park T. S.,Andriolo G.,Sun B.,Zheng B.,Zhang L.,Norotte C.,Teng P. N.,Traas J.,Schugar R.,Deasy B. M.,Badylak S.,Buhring H. J.,Giacobino J. P.,Lazzari L.,Huard J.,Peault B..A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs.Cell Stem Cell. 2008;3:301-313
67.
Gururaja T. L.,Goff D.,Kinoshita T.,Goldstein E.,Yung S.,McLaughlin J.,Pali E.,Huang J.,Singh R.,Daniel-Issakani S.,Hitoshi Y.,Cooper R. D.,Payan D. G..R-253 Disrupts Microtubule Networks in Multiple Tumor Cell Lines.Clin. Cancer Res. 2006;12:3831-3842
68.
Wilson C. J.,Si Y.,Thompsons C. M.,Smellie A.,Ashwell M. A.,Liu J. F.,Ye P.,Yohannes D.,Ng S. C..Identification of a Small Molecule that Induces Mitotic Arrest Using a Simplified High-Content Screening Assay and Data Analysis Method.J. Biomol. Screen. 2006;11:21-28
69.
Kittler R.,Pelletier L.,Heninger A. K.,Slabicki M.,Theis M.,Miroslaw L.,Poser I.,Lawo S.,Grabner H.,Kozak K.,Wagner J.,Surendranath V.,Richter C.,Bowen W.,Jackson A. L.,Habermann B.,Hyman A. A.,Buchholz F..Genome-Scale RNAi Profiling of Cell Division in Human Tissue Culture Cells.Nat. Cell Biol. 2007;9:1401-1412
70.
Paul S. M.,Mytelka D. S.,Dunwiddie C. T.,Persinger C. C.,Munos B. H.,Lindborg S. R.,Schacht A. L..How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge.Nat. Rev. Drug Discov. 2010;9:203-214
71.
Hunter J.,Stephens S..Is Open Innovation the Way Forward for Big Pharma?.Nat. Rev. Drug. Discov. 2010;9:87-88
Overington J. P.,Al-Lazikani B.,Hopkins A. L..How Many Drug Targets Are There?.Nat. Rev. Drug Discov. 2006;5:993-996
74.
Yildirim M. A.,Goh K. I.,Cusick M. E.,Barabasi A. L.,Vidal M..Drug-Target Network.Nat. Biotechnol. 2007;25:1119-1126
75.
Nature. 2004;431:931-945
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
